Publication:
Demineralized Bone matrix add-on for acceleration of bone healing in atypical subtrochanteric femoral fracture: A consecutive case-control study

dc.contributor.authorNoratep Kulachoteen_US
dc.contributor.authorPaphon Sa-Ngasoongsongen_US
dc.contributor.authorNorachart Sirisreetreeruxen_US
dc.contributor.authorPongsthorn Chanplakornen_US
dc.contributor.authorPraman Fuangfaen_US
dc.contributor.authorChanyut Suphachatwongen_US
dc.contributor.authorWiwat Wajanavisiten_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-12-11T02:22:53Z
dc.date.accessioned2019-03-14T08:04:12Z
dc.date.available2018-12-11T02:22:53Z
dc.date.available2019-03-14T08:04:12Z
dc.date.issued2016-01-01en_US
dc.description.abstract© 2016 Noratep Kulachote et al. Background. Delayed union and nonunion are common complications in atypical femoral fractures (AFFs) despite having good fracture fixation. Demineralized bone matrix (DBM) is a successfully proven method for enhancing fracture healing of the long bone fracture and nonunion and should be used in AFFs. This study aimed to compare the outcome after subtrochanteric AFFs (ST-AFFs) fixation with and without DBM. Materials and Methods. A prospective study was conducted on 9 ST-AFFs patients using DBM (DBM group) during 2013-2014 and compared with a retrospective consecutive case series of ST-AFFs patients treated without DBM (2010-2012) (NDBM group, 9 patients). All patients were treated with the same standard guideline and followed up until fractures completely united. Postoperative outcomes were then compared. Results. DBM group showed a significant shorter healing time than NDBM group (28.1 ± 14.4 versus 57.9 ± 36.8 weeks, p = 0.04). Delayed union was found in 4 patients (44%) in DBM group compared with 7 patients (78%) in NDBM group (p > 0.05). No statistical difference of nonunion was demonstrated between both groups (DBM = 1 and NDBM = 2, p > 0.05). Neither postoperative infection nor severe local tissue reaction was found. Conclusions. DBM is safe and effective for accelerating the fracture healing in ST-AFFx and possibly reduces nonunion after fracture fixation. Trial registration number is TCTR20151021001.en_US
dc.identifier.citationBioMed Research International. Vol.2016, (2016)en_US
dc.identifier.doi10.1155/2016/4061539en_US
dc.identifier.issn23146141en_US
dc.identifier.issn23146133en_US
dc.identifier.other2-s2.0-84962306840en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/43128
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84962306840&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectImmunology and Microbiologyen_US
dc.titleDemineralized Bone matrix add-on for acceleration of bone healing in atypical subtrochanteric femoral fracture: A consecutive case-control studyen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84962306840&origin=inwarden_US

Files

Collections